In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. A gene expression signature associated with sensitivity to ...
Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis No significant financial relationships to ...
Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...
Itay: Researchers have found in a new study that a single postoperative dose of Mitomycin C significantly reduces early ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, ...
Complete response at 3 months was 79.6% (191/240), with duration-of-response estimates showing a gradual attrition over time ...
Renal and Urology News, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...
PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty ...
Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results